- |||||||||| Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi
Trial completion, Trial completion date: ZEBRA: Ziv-aflibercept Efficacy in Better Regulating AMD (clinicaltrials.gov) - Oct 5, 2020 P2, N=62, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2020
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Oct 4, 2020 The mean decrease of mPEDH and cPEDH at the last follow-up after switching was significantly larger in the IVR subgroup than in the IVB subgroup (p=0.023 and 0.010). Our results indicate that switching from intravitreal conbercept injections to bevacizumab or ranibizumab can lead to significant improvement of CMT, PED, and IRF and slight improvement of BCVA in a short period of time for persistent nAMD patients.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Intravitreal Therapies Pattern of Use in Italy- A Real-World Evidence Study on Maculopathies () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1462; 56 eyes treated for a 24-month time horizon, were administered with 5.52±0.36(range:1-6) ranibizumab injections. CONCLUSIONS : The study highlights differences between clinical practice and prescribing information, in terms of intravitreal injections frequency, suggesting the need to further analyze and describe reasons and related organizational factors and potential problems.
- |||||||||| [VIRTUAL] Budget IMPACT MODEL of the Dexamethasone Intravitreal Implant in Applicator () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_84;
The resources released would allow treatment of 759 to 1,293 new patients over 12 months, with the potential benefit of reduced waiting lists. CONCLUSIONS : The results show that incremental use of DXI is associated with significant economic advantages in both simulations, with estimated cost savings being directly proportional to its degree of market penetration.
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Idiopatic macular telangectasy type 1 (MacTel-1) different treatment approaches (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1532; MacTel type 1 is a rare vascular disease, this makes the decision of an optimal treatment difficult since several modalities cannot be evaluated in a randomized controlled protocol, therefore, the treatment guidelines are not well defined.The focal laser proved to be a good treatment alternative. However, it is not without visual adverse effects.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
[VIRTUAL] 36 months after ILUVIEN® (fluocinolone acetonide, FAc, 0.2μg/day) in eyes with persistent and recurrent diabetic macular edema: to reinject or not to reinject? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1509; The eye that received a second ILUVIEN® implant at month 39 had visual and anatomical gains, maintained for at least another year.On the other hand, the case kept its macula dry, with absence of edema after almost 5 years, without requiring any additional reinjection. The multifactorial nature of DME is responsible for the need of an individualized treatment for DME and explains why some patients need a second ILUVIEN® after 3 years to achieve a successful outcome for the patient, while, in others, one ILUVIEN® can lead to sustained control of inflammation and, consequently, prevent the recurrence of edema, without need of reinjection.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis, fingolimod / Generic mfg., Novus Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Branch retinal venous occlusion in a fingolimod-treated patient: a case report (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1507; It blocks the exit of lymphocytes from lymphatic tissue to the blood, protecting the central nervous system from lymphocytes attacking myelin. Fingolimod achieves that effect joining to esphingosine-1 phosphate receptors of lymphocytes.
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy of ranibizumab plus aflibercept therapy with dexamethosone intravitreal injection in patients with diabetic macular edema: 1 year follow-up (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1497; Purpose: Evaluate the macular thickness and visual acuity after the treatment using aflibercept plus ranibizumab with dexamethasone intravitreal injection in diabetic macular edema€™s eyes... We can state through this study that the treatment of diabetic macular edema with anti-VEGF associated with corticosteroid has a greater benefit than the treatment with these single drugs, shown by optical coherence tomography.Visual acuity increased with the association of drugs regardless of which antiangiogenic drug used.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-phospholipid syndrome and retinal vein occlusion (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1468; This case of combined BRVO and CRVO serves as a reminder to evaluate coagulation times and screening for APLA in patients with vaso-occlusive retinal disease, even if they are not free of conventional risk factors. Anti-coagulation therapy should be started, and the patient should be carefully followed up during the treatment period to prevent other serious complications and recurrent thrombosis.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] A retrospective study of eyes with diabetic macular edema (DME) refractory to anti-VEGF treatment in a tertiary hospital in the United Kingdom (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1466; This study highlights the burden of DME treatment being refractory to anti VEGF in a significant proportion of our cases along with the numerous visits made for their treatments.The management of these patients include switching between anti-VEGF treatments, increasing the frequency of injections and switching to another class of drugs e.g. intravitreal steroids. Furthermore, the current COVID 19 pandemic has placed further challenges on the healthcare system to provide a safe delivery of treatment to our patients.Although retrospective nature of the study and lack of electronic data recording limits its conclusions this study establishes DME becoming refractory over time (57% in 2.5 years) and a need for alternative or rescue treatment options after revising the definition for non-responsive / refractory cases.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Prognostic criteria determining the favorable and unfavorable course of myopic choroidal neovascularization (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1461; Thus, based on the data of the comparative analysis, the prognostic criteria for the adverse course of mCNV and resistance to anti-VEGF therapy can be considered: the axial length of the eyeball is more than 28 mm; a critical decrease in the thickness of the choroid on average to 50.0 ± 2.7 microns; a subretinal neovascular membrane that forms according to type 3 of the pattern; the predominant change in the menstrual-ovarian cycle according to the type of amenorrhea and opsomenorrhea; a 2-fold increase in the concentration of lipoprotein (a) above the reference values; increased concentration of sex and pituitary hormones. The use of multidisciplinary approaches for this disease will increase the effectiveness of treatment and prevent the development of relapses of mCNV and clinically pronounced changes in the double eye.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Clinical assessment of surgical treatment of acute postoperative endophthalmitis (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1377; An increase in cases of verification of methicillin-resistant staphylococcus strains causes some caution. Vancomycin - resistant strains were not detected.Emergency vitreoretinal surgery with intraviral administration of a combination of antibacterial drugs allows to restore visual function in acute postoperative endophthalmitis.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-VEGF in the treatment of choroidal neovascular membrane secondary to Stargardt’s disease (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1333; On the basis of our findings, intravitreal anti-VEGF injection seems to induce total regression of CNV secondary to Stargardt´s disease so it must be considered in the treatment of this complication. Furthermore OCTA provides a useful approach for CNV`s diagnosis as well as for monitoring and evaluating the treatment of intravitreal anti-VEGF so it could be a useful tool in clinical practice.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Macular star and capillary macroaneurysm in MacTel type-1: value of the study with multimodal imaging (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1140; The multimodal imaging study contributes significantly to a better understanding and diagnosis of different pathologies of the retina. This case enhances the use of laser photocoagulation as the standard treatment for mactel type 1 obtaining in this particular case poor results with intravitreal corticosteroids or intravitreal anti-vascular endothelial growth factor agents.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] What happens after stopping the T&E regimen in neovascular AMD? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1073; A high unmet need still remains for further education on nAMD disease assessment and utilizing evolving technologies. The decision to stop treating a patient who has responded well to treatment should be evaluated in some cases, especially in type 3 neovascular lesions that have already lost central vision in the other eye due to this disease.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Recurrent RPE apertures in a patient with CNVM: a continuum? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1068; Development of CNVM and RPE aperture in AMD may indicate a continuum with RPE aperture indicating atrophy while the development of CNV being a complication of a breach in RPE-Bruch’s complex. This case also illuminates the fact that intact ellipsoid zone and ELM is more important for visual acuity than RPE .
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Subretinal fibrosis in nAMD in the era of anti-VEGF treatment (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1064; It is driven mostly by myofibroblasts, although many types of cells may contribute to this process. The occurrence of subretinal fibrosis during the treatment of nAMD is an indicator of poor visual acuity in those patients.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Review of UK real-world outcomes of anti-VEGF therapy for neovascular AMD (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1060; Outcomes have improved as more proactive treatment regimens have been adopted with more frequent intravitreal injections. There is an unmet need for longer acting anti-VEGF therapies that would reduce the treatment burden for patients, carers and healthcare systems and make replication of impressive clinical trial results possible in the NHS.
|